leisure time -WSS

leisure time

author：explore 2025-09-28 00:51:51 - browse：61973

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： The EU Joint Clinical Assessment needs to live up to its promise

Wikipedia

WSS

Readout LOUD podcast: Merger Mondays, Ozempic panic

Beam Therapeutics to lay off 20% of its staff, re

Solve the antibiotic resistance crisis with preventive drugs

What's changing in Medicare's open enrollment this year?

Massive project maps cells in human brain in unprecedented detail

FDA struggles to regulate food additives, sometimes for decades

explore

leisure time

hotspot

Walensky prepares to leave CDC — and Congress — behind

Senate committee scrutinizes Medicare Advantage brokers

Virginia high school admissions case could be legal follow

CEOs share strategies for surviving biotech slump

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Novavax promises a turnaround & Lilly roils the obesity market

Peter Marks talks Operation Warp Speed for Rare Diseases

Virginia high school admissions case could be legal follow

Female surgeons have lower rates of long

focus

A revolution in caring for preterm infants

Hospital price transparency does save money, advocate argues

FDA struggles to regulate food additives, sometimes for decades

Eight reasons why you should get an updated Covid vaccine

STAT Readout Newsletter: Today in biotech, life science news

CEOs share strategies for surviving biotech slump

hotspot

leisure time

Wikipedia

knowledge